Patents by Inventor Casey C. Lynch
Casey C. Lynch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230142714Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: ApplicationFiled: May 9, 2022Publication date: May 11, 2023Applicant: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Publication number: 20220204457Abstract: Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, Formula Ia, and Formula Ib, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 20, 2020Publication date: June 30, 2022Inventors: Robert A. Galemmo, Andrei W. Konradi, Casey C. Lynch, Stephen S. Dominy
-
Patent number: 11325884Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: GrantFiled: June 11, 2020Date of Patent: May 10, 2022Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Publication number: 20210355527Abstract: Methods for detecting microbial nucleic acids in a body fluid of a subject are provided. The methods include highly sensitive and specific procedures for detecting DNA derived from the bacteria such as Porphyromonas gingivalis, e.g., using PCR amplification and qPCR detection, in clinical and/or laboratory samples containing CSF or other biofluids.Type: ApplicationFiled: September 27, 2019Publication date: November 18, 2021Applicant: Cortexyme, Inc.Inventors: Debasish Raha, Leslie J. Holsinger, Stephen S. Dominy, Casey C. Lynch
-
Publication number: 20210340105Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 8, 2021Publication date: November 4, 2021Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Casey C. Lynch
-
Patent number: 11059786Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: November 8, 2019Date of Patent: July 13, 2021Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Casey C. Lynch
-
Publication number: 20210053908Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: ApplicationFiled: June 11, 2020Publication date: February 25, 2021Applicant: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Patent number: 10906881Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 9, 2018Date of Patent: February 2, 2021Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 10730826Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: GrantFiled: March 14, 2019Date of Patent: August 4, 2020Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Publication number: 20200148642Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 8, 2019Publication date: May 14, 2020Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Casey C. Lynch
-
Publication number: 20190210960Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: ApplicationFiled: March 14, 2019Publication date: July 11, 2019Applicant: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Publication number: 20180334440Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 9, 2018Publication date: November 22, 2018Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 7105289Abstract: The present invention provides imprint bead compositions useful for capturing, isolating, detecting, analyzing and/or quantifying molecules in a sample. The imprint bead compositions comprise a matrix material having imprint cavities of a template molecule or molecules imprinted thereon wherein a substantial number of the imprint cavities are located at or near the surface of the matrix material.Type: GrantFiled: April 11, 2002Date of Patent: September 12, 2006Assignee: Aspira Biosystems, Inc.Inventors: Chin-Shiou Huang, Casey C. Lynch, Alexander Strikovsky
-
Publication number: 20030165882Abstract: The present invention provides imprint bead compositions useful for capturing, isolating, detecting, analyzing and/or quantifying molecules in a sample. The imprint bead compositions comprise a matrix material having imprint cavities of a template molecule or molecules imprinted thereon wherein a substantial number of the imprint cavities are located at or near the surface of the matrix material.Type: ApplicationFiled: April 11, 2002Publication date: September 4, 2003Inventors: Chin-Shiou Huang, Casey C. Lynch, Alexander Strikovsky
